There is decreased activity of glutamate carboxypeptidase II (GCP II) in the dorsolateral prefrontal cortex (DLPFC) and hippocampus of patients with schizophrenia. GCP II hydrolzses N-acetyl-a L-aspartyl-L-glutamate (NAAG), a peptide in the mammalian brain that binds to the N-methyl D-aspartate (NMDA) receptor and a group II metabotropic glutamate receptor, both of which have been implicated in the pathophysiology of schizophrenia. We examined the expression of GCP II mRNA in the DLPFC, entorhinal cortex (ERC), and hippocampus in postmortem samples from patients with schizophrenia and normal controls using in situ hybridization followed by silver grain detection. GCP II mRNA was detected in glial cells. Glial-rich regions, specifically the DLPFC and ERC white matter and the molecular and polymorphic layers in the hippocampus, express high levels of GCP II mRNA. Given the earlier finding of decreased GCP II activity in brains of subjects with schizophrenia, we expected to find lower GCP II mRNA levels in schizophrenia. Contrary to this expectation, we found a significantly higher expression of GCP II mRNA in one of the brain areas examined, the hippocampal CA3 polymorphic region. This may reflect a compensatory increase to correct for the decreased activity of GCP II activity. Our findings support the notion that the hydrolysis of NAAG is disrupted in schizophrenia and that specific anatomical regions may show discrete abnormalities in GCP II synthesis.
INTRODUCTION
Glutamate, the major excitatory neurotransmitter in the mammalian brain, has been implicated in the pathophysiology of schizophrenia (reviewed in Tsai and Coyle, 2002) . However, the precise nature of this abnormality has not been elucidated, partially because regulation of glutamate synthesis, release, receptor activation, and glutamate breakdown is complex and often difficult to study directly at sufficient spatial and temporal resolution in patients with schizophrenia. One important discovery implicating glutamate receptors is the finding that antagonists of the Nmethyl-D-aspartate (NMDA) receptor, phencyclidine (PCP; Javitt and Zukin, 1991) , and ketamine (Krystal et al, 1994) can cause positive, negative, and cognitive symptoms resembling schizophrenia in healthy individuals and can exacerbate psychotic symptoms in patients with schizophrenia (Lahti et al, 1995 (Lahti et al, , 2001 . By blocking a subpopulation of NMDA receptors, the dissociative anesthetics, like PCP, increase glutamate release in the prefrontal cortex and nucleus accumbens in rodents, producing behaviors that mimic the schizophrenic state, such as increased locomotor activity, stereotypies, and impaired performance on working memory tasks (Moghaddam and Adams, 1998) . The pretreatment of these animals with a group II metabotropic glutamate receptor agonist (group II mGluR), LY 354740, prevents the glutamate efflux and abolishes some of the PCP-induced behaviors. Another potent mGluR2/3 receptor agonist, LY 379268, has been shown to attenuate selectively PCP-evoked increases in motor activity in a manner similar to the effect of the atypical antipsychotic, clozapine (Cartmell et al, 2000) . Taken together, these data suggest the involvement of NMDA receptors and group II mGluRs in the pathophysiology of schizophrenia.
An endogenous peptide, N-acetylaspartateglutamate (NAAG) targets both the NMDA receptor and one of the group II mGluRs, that is mGluR3. It may function as a weak agonist at NMDA receptors (Westbrook et al, 1986; Trombley and Westbrook, 1990; Sekiguchi et al, 1992) , and is a highly selective agonist at mGluR3 receptors (Wroblewska et al, 1998) . NAAG is the most prevalent and widely distributed neuropeptide in the mammalian nervous system (reviewed in Coyle, 1997; Neale et al, 2000) . It meets criteria for classification as a neurotransmitter, being concentrated in synaptic vesicles (Williamson and Neale, 1988a; Renno et al, 1997) released in a calcium-dependent manner upon depolarization (Williamson and Neale, 1988b; Tsai et al, 1990) , and is hydrolyzed by membrane-bound peptidase. Immunocytochemical studies reveal colocalization of NAAG in many putative glutamatergic pathways in the human brain (Passani et al, 1997) . Glutamate carboxypeptidase II (GCP II; previously known as N-acetyl-a-linked acidic dipeptidase, NAALADase) is one enzyme that cleaves NAAG to N-acetylaspartate (NAA) and glutamate (Slusher et al, 1990) .
Activity of GCP II determines the relative extracellular levels of NAAG and glutamate (Stauch-Slusher et al, 1989) . NAAG has predominantly inhibitory actions by virtue of its possible weak agonist activity at the N-methyl-D-aspartate receptor, blocking the gating of the channel by endogenous glutamate, with agonist activity at the mGluR3 receptor that is negatively linked to cAMP (Neale et al, 2000) . There is evidence of decreased activity of GCP II in the PFC (À37%) and hippocampus (À28%), with decreased glutamate levels in these regions, and increased NAAG levels in the hippocampus of the schizophrenic brain compared to normal controls (Tsai et al, 1995) . In vivo, magnetic resonance spectroscopic imaging has revealed selective reductions in NAA in the dorsolateral prefrontal cortex (DLPFC) and hippocampus in schizophrenia (Bertolino et al, 1996; Deicken et al, 1999) . Additionally, the GCP II gene is in proximity to the breakpoint region in chromosome 11 of the schizophrenia-linked translocation t (1 : 11) (q42.1, q14.3) (Semple et al, 2001) , suggesting its candidacy as a susceptibility gene for schizophrenia.
This study was performed with the aim to elucidate the cell specificity and expression pattern of GCP II mRNA in the DLPFC and mesial temporal cortex in the normal primate brain, and to compare levels of expression to patients with schizophrenia. Our initial hypothesis, based on findings of decreased GCP II activity in schizophrenia, was that there is a decrease in GCP II mRNA levels in schizophrenia. As discussed later in the paper, we found an increase in GCP II mRNA levels in a specific hippocampal region.
RESULTS

DLPFC
Cohort 1, consisting of subjects with schizophrenia and normal controls, was used to perform the analysis of GCP II mRNA in the DLPFC (Table 1) . We did not find significant differences between these two groups in terms of age (df 1,27 , p ¼ 0.89), pH (df 1,27 , p ¼ 0.90), or postmortem interval (PMI; df 1,27 , p ¼ 0.11). There were no significant correlations between GCP II mRNA and any of the demographic variables (pH, PMI, age, lifetime exposure to antipsychotic medication) analyzed (all R between À0.09 and 0.24, all p40.2).
The normal distribution of GCP II mRNA in the DLPFC was examined in humans and monkey sections using in situ hybridization. GCP II mRNA hybridization signal from the autoradiographic films was found in a similar distribution in monkey and human brain. In the human, the GCP II mRNA signal was detected in gray matter areas of the middle frontal gyrus, but was more intense in the underlying white matter. Similarly, the GCP II signal in the monkey was low in gray matter areas along the bank of the principle sulcus, but was more intense in the underlying white matter (Figure 1a,b) . This finding suggests that nonneuronal cells that are predominantly found in the white matter, such as astrocytes and/or oligodendrocytes, may be the primary sites of synthesis of GCP II in the primate brain. Silver grain analysis, performed in the monkey sections, revealed that silver grains corresponding to GCP II mRNA were clustered over cells with a glial profile and were absent over neurons (Figure 1c,d) . The GCP II silver grains found overlying cells with small nuclei that were stained with Nissl supports the conclusion that GCP II synthesis occurs predominantly in glia, either astrocytes or olidodendrocytes, rather than in neurons. GCP II mRNA is known to be expressed in cells that coexpress glial fibrilliary acidic protein (GFAP) and an astrocyte-specific glutamate transporter, GLAST (Berger et al, 1999) , suggesting that GCP II mRNA is expressed primarily by astrocytes. The expression pattern described for GCP II mRNA in the DLPFC in both gray and white matter was similar in both normal controls and patients with schizophrenia. The mixed model ANOVA did not show a main effect of diagnosis (F ¼ 0.41, df 1,27 , p ¼ 0.53) on GPC II mRNA levels in DLFPC of patients with schizophrenia compared to controls. However, as expected, there was a main effect of area with higher levels of GCP II mRNA in white matter compared to gray matter (F ¼ 65.12, df 1,27 , po0.001). The interaction between diagnosis and region was not significant (F ¼ 0.38, df 1,27 , p ¼ 0.54). The removal of cases with highest PMIs (cases S6 and S7) resulted in a more closely matched cohort (age (df 1,25 , p ¼ 0.58); pH (df 1, 27 , p ¼ 0.2; PMI df 1, 25 , p ¼ 0.40). Analysis with this cohort also did not show any significant effect on GCP II mRNA levels in the PFC between the two diagnostic groups (effect of diagnosis F ¼ 0.44, df 1,25 , p ¼ 0.51; effect of area F ¼ 53.7, df 1,25 , po0.001; interaction between diagnosis and area F ¼ 0.65, df 1,25 , p ¼ 0.43).
Hippocampal Region
Cohort 2 consisting of two groups, subjects with schizophrenia and normal controls, was used to examine the GCP II mRNA expression in the hippocampus. Using a t-test, there was no significant difference between the two groups for age (df 1, 19 , p ¼ 0.96), pH (df 1, 19 , p ¼ 0.89), or PMI (df 1,19 , p ¼ 0.17). Correlations were seen in GCP II mRNA levels and pH (all R between 0.05 and 0.64, all p40.002). No significant correlations between GCP II mRNA levels and PMI or age were detected.
GCP II mRNA was detected in all mesial temporal lobe sections examined from both patients and controls (Figure 2a, 3) . In the dentate gyrus and Ammon's horn of the hippocampus, GCP II mRNA was abundant in the polymorphic layer (Figure 2a , arrow) as well as near the pial surface of the fused hippocampal fissure (Figure 2a arrowhead), while expression within the granule cell layer and pyramidal neuronal layer was minimal. In fact, the expression pattern was inverse to that typically seen in the hippocampus with other RNA probes that hybridize strongly to neurons. Microscopic evaluation demonstrated the presence of GCP II mRNA over glial cells (Figure 2c ). Highest density of signal of GCP II mRNA was found in Ammon's horn in a band curving along the ventricular surface; this polymorphic layer is enriched with astroglial cells and the increased hybridization signal found here is consistent with a predominately glial localization of GCPII mRNA (Du et al, 1990) . In further support of the glial localization of GCP II mRNA, silver grains were clustered over glial cell nuclear profiles ( Figure 2e ). A similar distribution was seen in the subiculum where the highest GCP II mRNA signal was detected in the superficial outer layer. In the entorhinal cortex, GCP II mRNA was higher in the white matter compared to the gray. This regional difference in GCP II mRNA levels was seen in both diagnostic groups. The comparison of GCP II distribution in the mesial temporal lobe of monkeys revealed a pattern of expression similar to that in the human (Figure 2b) . At the cellular level, silver grains were localized to glial cells in both humans and monkeys (Figure 2c -f). We tested whether GCPII mRNA levels differed in the hippocampus of patients with schizophrenia vs controls. While we did not detect a main effect of diagnosis (F ¼ 1.81, df 1,12 , p ¼ 0.20), we did detect a significant main effect of area (F ¼ 24.34, df 1,117 , po0.001) and a significant interaction between diagnosis and region (F ¼ 2.63, df 1,117 , p ¼ 0.008). This result was followed up with post hoc t-tests, which showed that GCP II mRNA levels were significantly higher in the CA3 polymorphic layer in patients with schizophrenia compared to controls (Figures 4 and 5; t ¼ 3.06, df 1,16 , p ¼ 0.0075). Since correlations were seen between GCP II mRNA levels and pH, an ANOVA with pH as the covariate was performed between GCP II levels in CA3 polymorphic layer and diagnosis. A significant increase in patients with schizophrenia was also found when pH was covaried (F ¼ 9.88, df ¼ 1,15 , p ¼ 0.0067). Levels of GCP II mRNA in the CA3 polymorphic layer were 197% of normal controls while in every other region analyzed (including the dentate gyrus, CA4, CA1, subiculum and entorhinal cortex), GCP II mRNA levels were between 73 and 119% of control levels ( Figure 5 ) but did not reach statistical significance (all t between À1.26 and 0.67, all p40.22).
We also did post hoc studies to examine further the significant main effect of brain area. Of all the regions investigated, the polymorphic layers of CA1 and CA3 and the superficial layer of the subiculum expressed the highest levels of GCP II mRNA. There was no difference in GCP II mRNA between these regions. However, the entorhinal cortex expressed significantly lower GCP II mRNA levels compared to these three regions (p ¼ 0.007-0.04). There were no significant differences in GCP II mRNA levels between neuron-dense regions in the mesial temporal lobe, namely between CA4, pyramidal layers of CA1 and CA3, and the deep subiculum or ERC gray matter.
DISCUSSION
Normal Distribution of GCP II
In this study, we have characterized the distribution pattern of GCP II mRNA in two cortical areas, DLPFC and ERC, and in subregions of the hippocampus. In all brain areas examined, expression of GCP II mRNA occurs primarily over glial cells, presumably astrocytes, while both pyramidal and nonpyramidal neurons are devoid of any message. These findings are consistent with reports in the rodent where GCP II mRNA colocalizes with the astrocytic marker, GFAP, and with Schwann cells but not neurons (LuthiCarter et al, 1998a, b; Berger et al, 1999) . Additionally, GCP II immunoreactivity in the rat hippocampus was enriched in synaptic-rich neuropil, while no intracellular staining was detected in pyramidal cells or their dendrites (Slusher et al, 1992) . Collectively, these data suggest that GCP II is expressed by astrocytes. Astrocytic endfeet wrap around neuronal synapses (Harris and Rosenberg, 1993) , placing GCP II at a location where it can perform its role in cleaving NAAG. Immunohistochemical human studies have revealed intense NAAG-like immunoreactivity (NAAG-LI) in pyramidal neurons and interneurons in the CA1-CA4 regions (Passani et al, 1997) , suggesting that NAAG, a peptide that meets criteria for a neurotransmitter, may be released at pyramidal and interneuron terminals. This released NAAG may be metabolized into NAA and glutamate by the glialderived GCP II. Indeed, glia are known to play instrumental roles in the metabolism and reuptake of many synaptically released neurotransmitters.
GCP II in Schizophrenia
Decreased GCP II activity in the DLPFC and hippocampus has been reported in schizophrenic subjects (Tsai et al, 1995) . However, we did not find any difference in GCP II mRNA levels in the DLPFC between normal controls and schizophrenic subjects. This suggests that the decreased GCP II activity may not be due to decreased expression of the GCP II transcript. Contrary to our initial hypothesis, we found a nearly two-fold increase (197%) in GCP II mRNA expression in the CA3 polymorphic layer in patients with schizophrenia.
The increase in GCP II mRNA levels is seen only in the CA3 polymorphic layer. The CA3 is a region selectively implicated as a specific site of pathology in schizophrenia in several studies. These have included reports of decreased AMPA and KA receptor subunits (Eastwood and Harrison, 1995a; Porter et al, 1997) , decreased NMDA receptor binding (Dean et al, 1999) , decreased excitatory aminoacid transporter 3 (EAAT3) mRNA (Bachus et al, 1996) , and reduced levels of synaptophysin (Eastwood et al, 1995b (Eastwood et al, , 1999 Webster et al, 2001) . It is interesting to note that these findings are observed in the CA3 region, while the adjacent CA1 is devoid of these neuropathological changes, suggesting a selective vulnerability of the CA3 region.
The CA3 polymorphic layer is comprised of basal dendrites from pyramidal neurons, interneurons, and glia (Amaral and Insausti, 1990; McBain and Fisahn, 2001) . Principal axons of the CA3 pyramidal neurons give rise to primary branches, many of which remain in the polymorphic layer and arborize extensively (Li et al, 1994) . It is estimated that 42-51% of the total dendritic length of a CA3 pyramidal neuron in the rat is located in the polymorphic layer (Ishizuka et al, 1995) , and that the majority of boutonladen collaterals are found in the polymorphic layer (64% in the study by Sik et al, 1993) . Within this layer there are three types of interneurons (oriens-lacunosum-moleculare (O-LM) interneuron, basket cells, and bistratified cells) that show domain-specific innervation of the pyramidal neuron. For example, O-LM interneurons project to distal dendrites of pyramidal neurons, while basket cells project to the pyramidal neuron soma and proximal dendrites (reviewed in McBain and Fisahn, 2001 ). The majority of contacts made between the CA3 pyramidal neurons and GABAergic neurons are in the polymorphic layer (63% in the study by Sik et al, 1993) . Synapses in the CA3 region at which NAAG may modulate neurotransmission include those between CA3 neurons, between GABAergic neurons, and GCP II in schizophrenia S Ghose et al between the CA3 neuron and GABAergic neuron (Figure 6 ). We can speculate that alterations in GCP II mRNA may lead to specific changes in GCP II activity and to very localized changes in NAAG and NAA concentrations. Altered NAAG levels at synapses in the CA3 polymorphic layer could result in the disruption of the recurrent inhibitory feedback/feed forward function that would impair the ability of the CA3 field, as a whole, in modifying incoming information and transferring the modified message to the CA1 field. The reasons for the discrepancy between the present findings with quantitative in situ hybridization for GCP II mRNA and those of the previous study in which GCP II activity was measured in postmortem tissue is unclear. It is possible that the increase in GCP II mRNA levels may reflect a compensatory response to normalize low GCP II enzyme activity. Further studies to quantify protein levels of GCP II in the CA3 polymorphic region may help address this issue. Alternatively, the difference between the previous and this study may reflect heterogeneity in the etiology of schizophrenia. In the earlier study showing decreased GCP II enzyme activity in schizophrenia, only 40% of subjects exhibited marked reductions in enzyme activity. Thus, only a subgroup of patients with schizophrenia may suffer from a reduction of GCP II activity. A third explanation for the difference may be the heterogeneity in the response to medications among patients in the two studies. Recent preclinical research reveals that both dissociative anesthetics such as phencyclidine and the antipsychotic, haloperidol, increase expression of GCP II as measured by quantitative Western blots in a regionally selective manner (Flores and Coyle, in press). Although we did not find any correlation between antipsychotic medication exposure and GCP II mRNA levels in this study, it is possible that subtle differences in drug exposure might also account for the differences between the two studies.
In summary, we have found that GCP II mRNA is expressed prominently by glia, probably astrocytes. GCP II gene expression is significantly different in the polymorphic layer of CA3 in schizophrenia, the CA3 region being one that has repeatedly been implicated in the pathophysiology of schizophrenia. Our results further support the finding that hydrolysis of NAAG is disrupted in the hippocampus of patients with schizophrenia.
MATERIALS AND METHODS
Brain Collection
Post-mortem brains were obtained from the Office of the Chief Medical Examiner in Washington, DC. Coronal slabs of the entire rostral-caudal extent of a hemisected brain (1-1.5 cm thick) were fresh frozen at the time of autopsy in a 50 : 50 mixture of isopentane and dry ice as previously described (Kleinmn et al, 1995) . The coronal slabs were bagged and stored at À801C until further dissection could be conducted. The DLPFC, located along the middle one-third of the middle frontal gyrus, was trimmed while frozen into a wedge-shaped block along the superior frontal sulcus/middle frontal gyrus of all cases. Brodmann's area 46 (BA 46) of the DLPFC was identified through Nissl staining according to defined cytoarchitectural criteria (Rajkowska and Goldman-Rakic, 1995) . Blocks (2-3) of the rostral mesial temporal lobe were sectioned from the amygdala through the body of the hippocampus; sections were stained and anatomically matched at the rostral midbody level of the hippocampus (Rosene and van Hoesen, 1987) . The cryostat sections (14 m thick) from both regions were mounted on gelatin-subbed slides and stored at À801C.
Tissue from Rhesus macaque monkeys was collected from normal adults according to NIH guidelines. Animals were perfused with normal saline under ketamine anesthesia. After removal of the brain from the skull, coronal slabs of brain were serially blocked in B1 cm increments, frozen in a 50 : 50 dry ice-isopentane slurry and stored at À801C. Sections were cut by cryostat (14 mm) in the coronal plane, collected on subbed slides and stored at À801C. Sections from the monkey brains containing the upper and lower banks of the principal sulcus (primate DLPFC, Area 46) and anterior hippocampus were used to compare regional and cellular expression patterns of GCP II in monkeys and humans (Paxinos et al, 2000) .
For the human studies, cohort 1 was used to perform the analysis of GCP II mRNA in the DLPFC, while cohort 2 was used in a separate experiment to examine the GCP II mRNA expression in the hippocampus. Most subjects were included in both cohorts (Table 1) . Cohort 1 included post-mortem brains from 29 individuals ranging in age from 18 to 83 years, while brains of 21 individuals ranging in age from 23 to 81 years were used in cohort 2. Each cohort consisted of two groups, patients with schizophrenia and normal controls. Cases were screened by police and/or by telephone interviews of family members for a history of medical and/or psychiatric illnesses including substance abuse. The human brains used were free of neuropathological changes as determined by gross and microscopic examination. Bielschowsky's silver stain was performed on multiple cortical areas to exclude neuritic pathology. Diagnostic groups within each cohort were matched as Figure 6 Schematic representation of synapses made between pyramidal neurons and interneurons in the polymorphic layer of CA3 in the hippocampus. The CA3 polymorphic layer is comprised of basal dendrites from pyramidal neurons, interneurons and glia. Principal axons of the CA3 pyramidal neurons give rise to primary branches, many of which remain in the polymorphic layer and arborize extensively. The majority of contacts made between the CA3 pyramidal neurons and GABAergic neurons are in the polymorphic layer.
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pH Determination
In each case, a frozen section of lateral cerebellum was pulverized over dry ice and 500 mg of the tissue was weighed. The sample was homogenized for 15 s in 5 ml of dH 2 O using a 7 mm diameter generator probe with a processing range from 0.25 to 10 ml (Omni International, Gainesville, VA) attached to a handheld tissue homogenizer (model Omni TH, Omni International Inc., Gainesville, VA). Tissue pH was measured on a model 370 PerpHeCT pH/ISE meter (AT1 Orion Analytical Technology Inc., Boston, MA) equipped with a PerpHeCT Ross glass electrode.
Riboprobe Design
The human GCP II cDNA that was provided from the laboratory of Dr Joseph Coyle was isolated from human LNCaP cell line (Luthi-Carter et al, 1998a, b) . The cDNA is a 2.5 kb insert in the pcDNA3 plasmid (Invitrogen) between the BamHI and XbaI sites. The antisense and sense templates were linearized using HindIII and ApaI, respectively. 35 S-UTP-labeled riboprobes with specific activities between 1.76 Â 10 9 and 2.39 Â 10 9 cpm/mg were synthesized using an in vitro transcription kit (Riboprobe Systems, Promega, Madison, WI) with SP6 polymerase and T7 polymerase to generate the antisense and sense riboprobes, respectively.
In situ Hybridization
Two 14 mm sections per region per case were used in each in situ hybridization experiment. Tissue sections were fixed, acetylated, delipidated and dehydrated, then hybridized with 35 S-UTP-labeled riboprobes overnight at 551C as previously described (Whitfield et al, 1990) . Control sections of PFC and hippocampus were hybridized with radiolabeled sense strand in the same experiment and under the same conditions. Following the in situ procedure, slides were apposed to Kodak autoradiographic film (Biomax) for 3-4 weeks along with 14 C standards (American Radiolabeled Chemicals, Inc., St Louis, MO). Once the autoradiographic films were developed, all the slides were dipped in photographic emulsion (Kodak Emulsion NTB-2), dried and subsequently developed in D-19 developer (Kodak) after 12-24 weeks. To maximize the silver grain signal for cellular analysis, additional slides of human hippocampus and primate PFC and hippocampus were immediately dipped in photographic emulsion after the in situ hybridization.
Image Analysis
Autoradiographic films were scanned using a HewlettPackard Scanjet Plus flatbed at 300 dpi resolution. The autoradiographic images were analyzed using the NIH Image software version v.1.61. (Rasband, NIH). Quantification of optical densities was performed blind to diagnosis in the DLPFC and regions in the hippocampal formation including the dentate gyrus, CA4, CA3, CA1, subiculum, and entorhinal cortex. In the DLPFC and ERC, measurements were taken from gray and white matter areas. For gray matter, sample areas traversed the entire cortex; for the white matter, samples were taken from the subcortical region. Within the Ammon's horn, areas were sampled from the region of highest signal intensity, the polymorphic layer (comprised of the stratum oriens and alveus), and the region of lowest signal intensity, the pyramidal layer (Figure 7 ). In the dentate gyrus, samples were taken from regions of highest signal that corresponded to the molecular layer. A 14 C standard curve was plotted for each cohort in order to calculate mCi/g of GCP II mRNA measured in each sample area. A total of 10 areas of interest were sampled from each of two slides available for each case. An average was obtained from the two slides for each area of interest. In four cases, it was not possible to sample every region due to inadvertent damage while processing the tissue.
Statistical Analysis
The demographic variables pH, PMI, and age were compared between cohorts using t-tests. Correlation with average GCP II mRNA levels in areas sampled with the pH, PMI, age, and lifetime exposure to antipsychotic medication were run with a Spearman Rank Order correlation. The effect of diagnosis on GCP II mRNA levels in specific regions was analyzed using a mixed model ANOVA with diagnosis as the between group factor and brain area as the within group factor. Significant findings were further analyzed using post hoc t-tests. GCP II mRNA values outside two SDs away from the mean for each area were considered outliers and were not included in the statistical analyses.
